Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Cochrane riska novērtēšanas rīks 2.0 randomizētiem kontrolētiem pētījumiem× | CONSORT Checklist: Standarti randomizētu kontrolētu pētījumu ziņošanai× | |
|---|---|---|
| Nozare | Pētniecības metodoloģija | Pētniecības metodoloģija |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 2019 | 2010 (original 1996) |
| Autors≠ | Jonathan Sterne, Julian Higgins (Cochrane Collaboration) | Schulz et al. (CONSORT Group) |
| Tips≠ | Clinician-rated / Research team assessment | Trial author reporting checklist |
| Pirmavots≠ | Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. DOI ↗ | Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The Lancet, 375(9721), 1657–1668. DOI ↗ |
| Citi nosaukumi | RoB 2.0, RoB 2 | CONSORT, CONSORT 2010 |
| Saistītās | 4 | 4 |
| Kopsavilkums≠ | RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias. | The CONSORT (Consolidated Standards of Reporting Trials) Statement is a 25-item evidence-based checklist and flow diagram developed to standardize reporting of parallel-group randomized controlled trials. First published in 1996 and updated in 2010 (CONSORT 2010), it is endorsed by over 600 journals including The Lancet, JAMA, and BMJ, and is mandatory or strongly recommended for RCT manuscript submission across clinical research. |
| ScholarGateDatu kopa ↗ |
|
|